Evidence map›Paper›PMID 39036582›Full record

ArticleJournal of community hospital internal medicine perspectives2024

Pembrolizumab-induced Myasthenia Gravis and Myocarditis.

Jisun Won, Edward Zhao, Melissa States, Rachel Brown, Abdallah El-Habr, Jason Damsker

Abstract readCase Reports
In one paragraph

Article in Journal of community hospital internal medicine perspectives, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jisun WonAbington Memorial Hospital, Department of Internal Medicine, USA.
Edward ZhaoAbington Memorial Hospital, Department of Internal Medicine, USA.
Melissa StatesAbington Memorial Hospital, Department of Internal Medicine, USA.
Rachel BrownAbington Memorial Hospital, Department of Internal Medicine, USA.
Abdallah El-HabrAbington Memorial Hospital, Department of Internal Medicine, USA.
Jason DamskerAbington Memorial Hospital, Department of Internal Medicine, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As the use of immune checkpoint inhibitors (ICPi) such as pembrolizumab is rapidly expanding in the field of immuno-oncology, it is crucial for healthcare providers to be aware of their immune-related adverse events (irAE) which are thought to be driven by augmented immune response of T-cells. While neurologic irAE are underrepresented in literature, their consequences could lead to fatal outcomes. In this report, we describe the case of a patient with excellent performance status prior to pembrolizumab therapy who subsequently suffered myasthenic crisis eventually requiring tracheostomy and long-term mechanical ventilation.

Indexed as

Immune checkpoint inhibitorsImmune-related adverse eventsMyasthenia gravisPembrolizumab

Identifiers

PMID39036582
PMCPMC11259487

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.